Welcome to our dedicated page for SAB Biotherapeutics news (Ticker: SABS), a resource for investors and traders seeking the latest updates and insights on SAB Biotherapeutics stock.
SAB Biotherapeutics, Inc. (NASDAQ: SABS) is a clinical-stage biopharmaceutical company pioneering in the development and commercialization of fully human polyclonal antibodies using its proprietary DiversitAb™ platform. Unlike traditional methods involving human plasma or serum, SAB leverages genetically engineered transchromosomic cattle (Tc Bovine™) to produce large volumes of human antibodies (immunoglobulin G) in response to specific antigens.
The company's core technologies aim to provide novel therapies for a wide range of immune and autoimmune disorders, including its lead asset SAB-142, which targets type 1 diabetes (T1D). SAB-142 is a human anti-thymocyte immunoglobulin designed to modulate the body's immune response, potentially delaying the onset and progression of T1D. This innovative approach has shown promise in early clinical trials, with Phase 1 studies demonstrating safety and biological activity without the adverse reactions commonly associated with animal-derived therapies.
Recent achievements include the FDA granting Breakthrough Therapy and Fast Track Designations to SAB-176, a fully human polyclonal antibody targeting multiple strains of Influenza A and B. This reflects the potential of SAB's platform to address unmet medical needs swiftly and effectively.
SAB is actively pursuing multiple projects and partnerships to expand its clinical pipeline. Notable collaborations include a pharmacokinetic and safety study for SAB-176, conducted in partnership with the Henry Jackson Foundation and the NMRC Clinical Trials Center. Additionally, SAB’s ongoing Phase 1 clinical trial for SAB-142 has successfully completed dosing the third cohort with no observed serum sickness.
Financially, SAB reported positive results for Q1 2024, with sufficient cash reserves expected to fund operations into 2026, assuming the exercise of outstanding Tranche B warrants. The company's strategic relocation of its headquarters to Miami, FL, and the recent appointment of Dr. Jay Skyler to its Board of Directors underscore its commitment to T1D research and treatment.
SAB Biotherapeutics continues to engage with the scientific and investment communities, providing regular updates on its progress and maintaining transparency in its forward-looking statements. As a pioneer in biopharmaceutical innovation, SAB is poised to make significant contributions to the treatment of immune and autoimmune disorders.
SAB Biotherapeutics (Nasdaq: SABS) reported its Q2 2022 financial results, highlighting a cash position of $16.6 million and a net loss of $4.8 million with EPS of $(0.11). Operating expenses are projected to be covered for the next twelve months. The company is advancing its pipeline with SAB 176 for anti-influenza entering Phase II development and SAB 195 targeting C. diff. moving towards pre-IND. A virtual R&D update is scheduled for August 17, 2022, to showcase its polyclonal immunotherapy platform, DiversitAb™.
SAB Biotherapeutics (SABS) has terminated its agreement with the U.S. Department of Defense due to misalignment of goals following modifications during the COVID-19 pandemic. This allows SAB to refocus on its core mission and advance its research pipeline, including the development of SAB-195, a polyclonal antibody treatment for Clostridioides difficile infection (CDI), which affects 500,000 people annually in the U.S. alone. SAB plans to file an IND within 18 months and anticipates announcing Phase 1 clinical trial results in 2024.
SAB Biotherapeutics (NASDAQ: SABS) announced a Virtual 2022 Annual R&D Portfolio Update on August 17, 2022, at 10:30 a.m. ET. The update will showcase the company's unique DiversitAb™ immunotherapy platform that produces high-potency, fully-human polyclonal antibodies without human donors. Executives will discuss planned clinical and preclinical development programs targeting diseases like COVID-19 and type 1 diabetes. A live webcast will be available, with a replay on the company's website. For registration details, visit www.sab.bio.
SAB Biotherapeutics (Nasdaq: SABS) announced the appointment of Rear Admiral Scott Giberson to its Board of Directors, effective July 7, 2022. Giberson, a retired two-star admiral with extensive government and healthcare experience, will bring valuable insights to the company. His previous roles include Deputy Surgeon General and Commander of the Commissioned Corps’ Ebola Response. SAB aims to leverage Giberson’s expertise to address unmet medical needs through its innovative immunotherapy platform. The company focuses on developing fully human polyclonal antibodies targeting diseases like COVID-19 and type 1 diabetes.
SAB Biotherapeutics (SABS) hosted Congressmen Dusty Johnson and Dean Phillips on July 1, 2022, at its Sioux Falls facility. The visit showcased SAB's innovative immunotherapy platform that produces fully human polyclonal antibodies through genetically engineered cattle. The Congressmen engaged with SAB's management team, discussing advancements in COVID-19 treatment and the company's pipeline targeting influenza, oncology, and type 1 diabetes. SAB aims to address unmet global health needs with its DiversitAb™ platform.
SAB Biotherapeutics (Nasdaq: SABS) announced the appointment of Dr. Alexandra Kropotova as Chief Medical Officer to enhance its pipeline in immune and autoimmune disorders. With over 20 years of experience, Dr. Kropotova previously led drug development at Teva Pharmaceuticals and has held key roles at Sanofi and Pfizer. Her expertise is expected to be vital for advancing SAB's initiatives in areas such as infectious diseases and cancer. The company continues to leverage its innovative platform for producing high-potency, fully human polyclonal antibodies.
SAB Biotherapeutics will present at the Large Animal Genetic Engineering Summit on June 7, 2022, in Park City, Utah. CEO Dr. Christoph Bausch will discuss advancements in their Transchromosomic (Tc) Goat platform for producing fully human polyclonal antibodies. The presentation will cover the DiversitAb platform, highlighting pipeline programs including SAB-185 (anti-SARS-CoV-2), SAB-176 (influenza), and SAB-142 (Type 1 diabetes). The company focuses on innovative immunotherapy solutions aimed at serious diseases.
SAB Biotherapeutics (Nasdaq: SABS) reported its Q1 2022 financial results and company updates, emphasizing significant advancements in its immunotherapy platform.
Key highlights include:
- Cash and cash equivalents of $22.4 million as of March 31, 2022.
- R&D expenses increased to $13.3 million, attributed to expanded capabilities.
- Net income was $1 million, equating to $0.02 per share.
Full data from the Phase 2a trial for SAB-176 is expected in Q3 2022, with additional updates on SAB-185 and other pipeline candidates anticipated later this year.
SAB Biotherapeutics (NASDAQ: SABS) will participate in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The company's management team is scheduled for a live Fireside Chat on May 25, 2022, at 9:00 am EDT. An on-demand webcast will be available on their website, allowing investors to access the presentation for 90 days post-event. SAB Biotherapeutics focuses on developing immunotherapies using fully human polyclonal antibodies for various diseases, including COVID-19 and type 1 diabetes.
SAB Biotherapeutics has appointed Dr. Mark J. Ratain to its Board of Scientific Advisors to enhance its oncology platform. Dr. Ratain, a prominent expert in cancer treatment and clinical pharmacology, has published over 500 academic works and will contribute his extensive knowledge to advance SAB's fully-human polyclonal antibody therapies.
CEO Eddie J. Sullivan expressed enthusiasm about Dr. Ratain's addition, emphasizing the potential benefits for the company’s targeted multivalent immunotherapies aimed at treating cancer.
FAQ
What is the current stock price of SAB Biotherapeutics (SABS)?
What is the market cap of SAB Biotherapeutics (SABS)?
What is SAB Biotherapeutics, Inc.?
What is the DiversitAb™ platform?
What is SAB-142?
What recent achievements has SAB Biotherapeutics reported?
Who are SAB's key partners?
Where is SAB Biotherapeutics headquartered?
What is the financial outlook for SAB Biotherapeutics?
How does SAB-142 differ from rabbit-derived ATG?
What is the focus of SAB's current clinical trials?
How can I learn more about SAB Biotherapeutics?
